Where we are now as ONCY shareholdersReading this board and Yahoo, there are two distinct camps of posters.
The bashers simply attack individuals, and comment about the 20 plus years of development, with a slowly declining share price and ongoing dilution.
It seems they did not really consider that this is a one virus, one product, zero revenue company that will look like a failure in the eyes of conventional investors, who are more familar with companies that have sales, growth and liquidity.
Oncy is a company that will look like it is failing from a conventional perspective, until it has a brekathrough.
The other camp, where I sit, sees ONCY as a risky investment that has taken time, but now the time for a breakthrough (or bust) is nearly here. The company has indicated that during Q2 we will hear about partnering (and by implication, possible purchase of the company).
The clinical results (which are the only thing that give ONCY value) have been stunning in how they seem to be getting better and better, with no negative or indifferent results since we started working toward trials that show our I/O combo potential.
I apprecaite the work of Noteable in reporting the science base around these kinds of drugs and also the market context. I appreciate CF for continuing to point out facts about ONCY while ignoring attackes on the Yahoo board.
Oncy is indeed a lottery ticket. The draw and resolution will occur this year. The downside (i.e. the breakup value if the company were somehow sold for its IP and the tax losses is vastly above the current price, given the results we have in hand. The most positive version of the upside is stratospheric as Noteable has indicated.
I bought into this company rather niavely, and have stuck with it because it basically has been getting better for five years. If they were still back at the strategy of direct cancer cell lysis, then indeed I would be very wary of the company, along the lines of the bashers.
But the bashers are alll looking backward, like 5 to 20 years backward, and are ignoring what has occurred in terms of trial releases in the last few years. That is what will decide our future, not their condemnation of the company because it does not look like other companies.